Accès ouvert · CC BY

Anandamide in First-Episode Psychosis: Associations with Symptoms and Inflammation

Résumé de communication 2026 Anglais

Résumé

Introduction Schizophrenia (SCZ) is a severe disorder with partially understood pathophysiology. The early stage is crucial for understanding pathogenic mechanisms and improving treatment strategies. Anandamide (AEA), a neurotransmitter of the endocannabinoid system, may be protective against psychosis. Objectives This study aimed to measure serum AEA levels in first-episode psychosis (FEP) at admission (T0) and remission (T1), compare them to healthy controls and explore clinical and inflammatory correlates of AEA levels Methods In a longitudinal observational study (Nov 2021–Dec 2023), 69 FEP patients and 74 controls underwent sociodemographic, clinical, psychometric assessment (PANSS, GAF, CGI, CAST) and blood tests (high sensitivity-CRP (hs-CRP), AEA, metabolic parameters). Results Patients were predominantly young, single men, with high unemployment; one-third used cannabis. At T0, AEA levels were significantly higher in patients than in controls (p = 0.045) and remained stable at T1. AEA showed consistent negative correlations with all PANSS subscales (e.g., total PANSS at T0: r = −0.45, p<0.001; T1: r = −0.41, p=0.034),and CGI-severity scale (At T0: r = −0.316, p = 0.008). Its elevation was independent of cannabis use, and its association with FEP persisted after adjustment (OR = 3.54, 95% CI = 1.32–9.46; p = 0.012). A positive correlation with hs-CRP was observed at T0 (r = 0.24, p = 0.048), independent of other confounding factors such as smoking and metabolic parameters. Conclusions AEA is elevated in FEP, inversely associated with symptom severity and positively correlated with inflammation, suggesting a potential neuroprotective and anti-inflammatory role. The endocannabinoid system may represent a promising target for novel therapeutic strategies. Disclosure of Interest None Declared

Citer ce document

Flah, W. B., Lansari, R., Kamoun, A., & Ghazzani, I. (2026). Anandamide in First-Episode Psychosis: Associations with Symptoms and Inflammation. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2026.10539

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 01/10/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Statistiques

Consultations (hors robots) : 8

Téléchargements (hors robots) : 0

Méthode de comptage